Page 52 - Read Online

Sooi et al. Cancer Drug Resist 2023;6:656-73 https://dx.doi.org/10.20517/cdr.2023.48 Page 668

DECLARATIONS
Authors’ contributions
Conceptualisation: Sooi K, Wong A, Ngoi N
Methodology: Sooi K, Walsh R, Wong A, Ngoi N
Writing: Sooi K, Walsh R, Kumarakulasinghe N, Wong A, Ngoi N
Supervision: Kumarakulasinghe N, Wong A, Ngoi N
Visualisation: Sooi K

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin 2021;71:209-49. DOI PubMed
2. Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment
options, and alternative approaches. Molecules 2022;27:5730. DOI PubMed PMC
3. Cancer stat facts: prostate cancer. Available from: https://seer.cancer.gov/statfacts/html/prost.html. [Last accessed on 19 Sep 2023].
4. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Available from: https://www.fda.gov/
drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication.
[Last accessed on 19 Sep 2023].
5. FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. Available from: https://www.fda.gov/drugs/
resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors. [Last
accessed on 19 Sep 2023].
6. Sedhom R, Antonarakis ES. Clinical implications of mismatch repair deficiency in prostate cancer. Future Oncol 2019;15:2395-411.
DOI PubMed PMC
7. de Bono JS, Guo C, Gurel B, et al. Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer 2020;20:455-69. DOI PubMed
8. Krueger TE, Thorek DLJ, Meeker AK, Isaacs JT, Brennen WN. Tumor-infiltrating mesenchymal stem cells: drivers of the
immunosuppressive tumor microenvironment in prostate cancer? Prostate 2019;79:320-30. DOI PubMed PMC
9. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell
infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009;348:9-17. DOI PubMed
10. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
DOI PubMed PMC
11. Garcia AJ, Ruscetti M, Arenzana TL, et al. Erratum for Garcia et al., Pten null prostate epithelium promotes localized myeloid-
derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol 2014;34:2017-28.
DOI PMC
12. Jamaspishvili T, Berman DM, Ross AE, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 2018;15:222-34.
DOI PubMed PMC
13. Zhang S, Ma X, Zhu C, Liu L, Wang G, Yuan X. The role of myeloid-derived suppressor cells in patients with solid tumors: a meta-